4-Antibody AG Announces a Long-Term Collaboration With Boehringer Ingelheim Corporation for Therapeutic Antibodies

4-Antibody AG Announces a Long-Term Collaboration With Boehringer Ingelheim Corporation for Therapeutic Antibodies; 4-Antibody AG will Receive Payments of up to EUR 177.5 Million

BASEL, Switzerland, March 16, 2010 /PRNewswire/ -- 4-Antibody AG today announces a major long-term collaboration with Boehringer Ingelheim to discover and to develop fully human therapeutic antibodies for a number of targets in various disease indications. 4-Antibody will use its proprietary and unencumbered Hu-PAC(R) and Retrocyte Display(R) technologies for the discovery and development of fully human antibodies against novel targets nominated by Boehringer Ingelheim. 4-Antibody AG will receive payments of up to EUR 177.5 million (CHF 266 million) including upfront and milestone payments from Boehringer Ingelheim upon achievement of certain clinical development milestones. Further financial details were not disclosed.

Dr. Ulf Grawunder, co-founder and CSO of 4-Antibody AG, said "This is a landmark agreement for 4-Antibody. We are delighted to commence a long-term collaboration with Boehringer Ingelheim and to apply the strength of 4-Antibody's fully human antibody discovery and engineering platforms to create valuable potential new drug candidates. Our unique and unencumbered technology capabilities allow the efficient generation of novel or improved fully human antibodies against any target class for our collaboration partners and for our own clinical development pipeline."

About 4-Antibody AG

4-Antibody AG is a privately held Swiss Biotech company active in the area of therapeutic antibody drug development. 4-Antibody AG has developed a portfolio of powerful, proprietary antibody discovery and engineering platforms, including the Hu-PAC(R) and the Retrocyte Display(R) technologies. 4-Antibody AG owns four patent families related to therapeutic antibody discovery platforms and products, including more than a dozen of granted patents worldwide. The company has 40 employees working at its headquarter in Basel, Switzerland, and its subsidiary in Jena, Germany.

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.